AU2015307873B2 - Heterobicyclic compounds and their use for the treatment of tuberculosis - Google Patents

Heterobicyclic compounds and their use for the treatment of tuberculosis Download PDF

Info

Publication number
AU2015307873B2
AU2015307873B2 AU2015307873A AU2015307873A AU2015307873B2 AU 2015307873 B2 AU2015307873 B2 AU 2015307873B2 AU 2015307873 A AU2015307873 A AU 2015307873A AU 2015307873 A AU2015307873 A AU 2015307873A AU 2015307873 B2 AU2015307873 B2 AU 2015307873B2
Authority
AU
Australia
Prior art keywords
methoxy
compound
chloro
fluoro
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015307873A
Other languages
English (en)
Other versions
AU2015307873A1 (en
Inventor
Yoshikazu Haraguchi
Norimitsu Hariguchi
Yohei Hayashi
Shunpei Ishikawa
Motohiro Itotani
Atsunori KANESHIGE
Yoshikazu Kawano
Makoto Matsumoto
Yuya NAKAI
Hiroshi Shimizu
Toshio Shinohara
Isao Takemura
Yukitaka UEMATSU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54105947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015307873(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU2015307873A1 publication Critical patent/AU2015307873A1/en
Application granted granted Critical
Publication of AU2015307873B2 publication Critical patent/AU2015307873B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
AU2015307873A 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis Active AU2015307873B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-174528 2014-08-28
JP2014174528 2014-08-28
PCT/JP2015/004371 WO2016031255A1 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Publications (2)

Publication Number Publication Date
AU2015307873A1 AU2015307873A1 (en) 2017-03-09
AU2015307873B2 true AU2015307873B2 (en) 2020-01-16

Family

ID=54105947

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015307873A Active AU2015307873B2 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Country Status (29)

Country Link
US (2) US10053446B2 (enExample)
EP (1) EP3186240B9 (enExample)
JP (1) JP6625612B2 (enExample)
KR (1) KR102418413B1 (enExample)
CN (1) CN106795117B (enExample)
AP (1) AP2017009788A0 (enExample)
AR (1) AR101704A1 (enExample)
AU (1) AU2015307873B2 (enExample)
BR (1) BR112017003231B1 (enExample)
CA (1) CA2959478C (enExample)
CY (1) CY1122286T1 (enExample)
DK (1) DK3186240T3 (enExample)
EA (1) EA038414B1 (enExample)
ES (1) ES2743788T3 (enExample)
HR (1) HRP20191486T2 (enExample)
HU (1) HUE045025T2 (enExample)
IL (1) IL250484B (enExample)
LT (1) LT3186240T (enExample)
MX (1) MX2017002312A (enExample)
MY (1) MY189098A (enExample)
NZ (1) NZ729064A (enExample)
PH (1) PH12017500290B1 (enExample)
PL (1) PL3186240T3 (enExample)
PT (1) PT3186240T (enExample)
SG (1) SG11201700882XA (enExample)
SI (1) SI3186240T1 (enExample)
TW (1) TWI687409B (enExample)
WO (1) WO2016031255A1 (enExample)
ZA (1) ZA201700916B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
JP6905506B2 (ja) * 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体
KR20210021042A (ko) 2018-06-15 2021-02-24 카딜라 핼쓰캐어 리미티드 포유동물 감염 치료를 위한 신규한 화합물
JP2023085582A (ja) * 2020-05-11 2023-06-21 大塚製薬株式会社 ジヒドロキノリノン化合物の共結晶
WO2022039506A1 (ko) * 2020-08-19 2022-02-24 주식회사 미토이뮨테라퓨틱스 Ｍabc-r 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
CN116102537B (zh) * 2021-11-10 2024-10-01 四川大学 一种喹啉酮类衍生物及其制备方法和用途
CN116589448B (zh) * 2023-04-24 2025-10-28 西南交通大学 一种3,4-二氢喹啉酮衍生物及其应用
WO2025183017A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010004347A1 (en) * 2008-07-10 2010-01-14 Prosidion Limited Heterocyclic gpcr agonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
TWI347946B (en) 2002-10-11 2011-09-01 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
AU2004285811B2 (en) * 2003-10-31 2008-06-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
ZA200602184B (en) * 2003-10-31 2007-10-31 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis
PL2489659T3 (pl) * 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
EP1988077A4 (en) 2006-02-23 2009-09-02 Shionogi & Co NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
RU2540860C2 (ru) 2009-07-31 2015-02-10 Глоубал Элаенс Фор Тб Драг Дивелопмент Нитроимидазооксазиновые и нитроимидазооксазольные аналоги и их применение
JP5916739B2 (ja) 2011-04-15 2016-05-11 大塚製薬株式会社 ６，７−ジヒドロイミダゾ［２，１−ｂ］［１，３］オキサジン化合物
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
JP6905506B2 (ja) * 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010004347A1 (en) * 2008-07-10 2010-01-14 Prosidion Limited Heterocyclic gpcr agonists

Also Published As

Publication number Publication date
CN106795117A (zh) 2017-05-31
MY189098A (en) 2022-01-25
PH12017500290B1 (en) 2023-07-19
CY1122286T1 (el) 2021-01-27
KR20170043644A (ko) 2017-04-21
HRP20191486T2 (hr) 2021-09-17
PT3186240T (pt) 2019-09-06
IL250484B (en) 2020-04-30
LT3186240T (lt) 2019-09-10
US20180312488A1 (en) 2018-11-01
AR101704A1 (es) 2017-01-04
US20170253576A1 (en) 2017-09-07
EP3186240A1 (en) 2017-07-05
EA038414B1 (ru) 2021-08-25
ZA201700916B (en) 2019-06-26
TWI687409B (zh) 2020-03-11
BR112017003231B1 (pt) 2022-10-11
WO2016031255A1 (en) 2016-03-03
CA2959478C (en) 2023-09-26
AU2015307873A1 (en) 2017-03-09
ES2743788T3 (es) 2020-02-20
EP3186240B9 (en) 2019-12-04
DK3186240T3 (da) 2019-08-26
HRP20191486T1 (hr) 2019-11-15
HUE045025T2 (hu) 2019-12-30
JP6625612B2 (ja) 2019-12-25
TW201609658A (zh) 2016-03-16
IL250484A0 (en) 2017-03-30
PL3186240T3 (pl) 2020-03-31
SG11201700882XA (en) 2017-03-30
BR112017003231A2 (pt) 2017-11-28
PH12017500290A1 (en) 2017-06-28
CA2959478A1 (en) 2016-03-03
SI3186240T1 (sl) 2019-10-30
CN106795117B (zh) 2020-06-26
NZ729064A (en) 2022-09-30
KR102418413B1 (ko) 2022-07-06
EA201790464A1 (ru) 2017-06-30
US10053446B2 (en) 2018-08-21
AP2017009788A0 (en) 2017-02-28
US10464926B2 (en) 2019-11-05
JP2017525697A (ja) 2017-09-07
EP3186240B1 (en) 2019-06-12
MX2017002312A (es) 2017-05-08

Similar Documents

Publication Publication Date Title
AU2015307873B2 (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
TWI873165B (zh) (雜)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
EP4021904B1 (en) Alpha-d-galactopyranoside derivatives
EP3774739B1 (en) Fused cyclic urea derivatives as crhr2 antagonist
CN103596960B (zh) 6,7-二氢咪唑并[2,1-b][1,3]噁嗪杀菌剂
KR20150132170A (ko) 야누스 키나제 억제제로서의 비-시클릭 시아노에틸피라졸로 피리돈
JP2008515796A (ja) 新規なピペリジン系抗生物質
JP6976691B2 (ja) 医薬組成物
US20080275035A1 (en) Nitroimidazole Compounds
EP1603901B1 (en) Tetrahydropyran compounds as tachykinin antagonists
OA18228A (en) Heterobicyclic compounds and their use for the treatment of tuberculosis.
HK1239683B (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
HK1239683A1 (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
KR20240165360A (ko) 에모파밀 결합 단백질 억제제 및 이의 용도
TW202321257A (zh) 可用於治療正黏液病毒感染之經取代之吡啶酮化合物
HK40072885A (en) Alpha-d-galactopyranoside derivatives
HK40072885B (en) Alpha-d-galactopyranoside derivatives
HK40043109A (en) Fused cyclic urea derivatives as crhr2 antagonist
HK40043109B (en) Fused cyclic urea derivatives as crhr2 antagonist
HK1207075A1 (en) Glucopyranosyl derivatives and their uses in medicine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)